Eylea fast-tracking through second NICE appraisal
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has issued positive final draft guidance for Bayer's Eylea (aflibercept solution for intravitreal injection, or VEGF Trap-Eye) in a second indication: visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). This recommendation also marks the second time Eylea has received a draft Final Appraisal Determination (FAD) without the need for additional consultation.